Pivkova-Veljanovska Aleksandra, Ivanovski Martin, Panovska-Stavridis Irina, Stojanoski Zlate, Trajkova Sanja, Karadzova-Stojanoska Angelika, Georgievski Borche, Kostadinova-Kunovska Slavica, Jovanovic Rubens, Petrushevska Gordana
University Clinic for Hematology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
Institute of Pathology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
Open Access Maced J Med Sci. 2019 Jun 5;7(11):1808-1811. doi: 10.3889/oamjms.2019.231. eCollection 2019 Jun 15.
Erdheim Chester disease (ECD) is a rare form of non-Langerhans histiocytosis that still presents a diagnostic and clinical dilemma.
We present a rare case of ECD, young 31 male with atypical localisation and soft tissue presentation and no bone involvement. He started clinical investigations due to subcutaneous tumour mass in the lumbar spine that caused severe back pain. Skin biopsy revealed ECD with Immunohistochemistry CD68+, CD10+, CD11c+, vimentin+, S100A4+. Activating BRAFV600E mutation was positive from the tumour tissue. The patient was referred to the haematology department. PET CT was performed for initial disease staging. Treatment was started with corticosteroids (methylprednisolone 0.5 mg/kg per day), and after 7 days, a significant clinical improvement was noticed in terms of pain disappearance with no need for pain killers. After two weeks, treatment with interferon Alfa (IFN-α) was started in a dose of 3 million units 3 times per week. After 4 months of interim treatment PET, CT revealed a significant reduction of the tumour mass. Therapy with IFN-α was continued, and the patient is still clinically in good condition.
It can be concluded that shortening the time of diagnosis of ECD is essential in treatment outcome of this disease. Still, large studies have to confirm the best treatment of this rare condition.
厄尔海姆-切斯特病(ECD)是一种罕见的非朗格汉斯组织细胞增多症,目前在诊断和临床方面仍存在困境。
我们报告一例罕见的ECD病例,患者为31岁男性,病变部位不典型且表现为软组织受累,无骨骼受累。他因腰椎皮下肿瘤肿块导致严重背痛而开始进行临床检查。皮肤活检通过免疫组织化学检测显示ECD,结果为CD68 +、CD10 +、CD11c +、波形蛋白 +、S100A4 +。肿瘤组织中BRAFV600E激活突变呈阳性。该患者被转诊至血液科。进行了PET CT检查以进行疾病初步分期。治疗首先使用皮质类固醇(甲泼尼龙,每天0.5 mg/kg),7天后,疼痛消失,无需使用止痛药物,临床症状有显著改善。两周后,开始使用干扰素α(IFN-α)治疗,剂量为每周3次,每次300万单位。经过4个月的中期治疗后,PET CT显示肿瘤肿块明显缩小。继续使用IFN-α治疗,患者目前临床状况良好。
可以得出结论,缩短ECD的诊断时间对该病的治疗结果至关重要。不过,仍需大型研究来证实这种罕见疾病的最佳治疗方法。